NO313954B1 - Fremgangsmåte for fremstilling av et radiofarmasöytisk avbildingsmiddel - Google Patents
Fremgangsmåte for fremstilling av et radiofarmasöytisk avbildingsmiddel Download PDFInfo
- Publication number
- NO313954B1 NO313954B1 NO19953756A NO953756A NO313954B1 NO 313954 B1 NO313954 B1 NO 313954B1 NO 19953756 A NO19953756 A NO 19953756A NO 953756 A NO953756 A NO 953756A NO 313954 B1 NO313954 B1 NO 313954B1
- Authority
- NO
- Norway
- Prior art keywords
- radiopharmaceutical
- phosphine
- agent
- chemical agent
- imaging
- Prior art date
Links
- 239000012217 radiopharmaceutical Substances 0.000 title claims description 34
- 229940121896 radiopharmaceutical Drugs 0.000 title claims description 34
- 230000002799 radiopharmaceutical effect Effects 0.000 title claims description 34
- 239000012216 imaging agent Substances 0.000 title claims description 9
- 238000004519 manufacturing process Methods 0.000 title description 2
- 238000000034 method Methods 0.000 claims description 14
- XYFCBTPGUUZFHI-UHFFFAOYSA-N phosphine group Chemical group P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- -1 thols Chemical class 0.000 claims description 8
- 239000013043 chemical agent Substances 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 7
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims description 7
- 235000010323 ascorbic acid Nutrition 0.000 claims description 6
- 150000003003 phosphines Chemical class 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- APRCRSUXFGXHEL-UHFFFAOYSA-N tris(3-methoxypropyl)phosphane Chemical group COCCCP(CCCOC)CCCOC APRCRSUXFGXHEL-UHFFFAOYSA-N 0.000 claims description 3
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical class OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 claims description 2
- 150000000994 L-ascorbates Chemical class 0.000 claims description 2
- 229910052796 boron Inorganic materials 0.000 claims description 2
- 150000001642 boronic acid derivatives Chemical class 0.000 claims description 2
- 150000003568 thioethers Chemical class 0.000 claims description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 2
- 235000021317 phosphate Nutrition 0.000 claims 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 7
- 229910052713 technetium Inorganic materials 0.000 description 7
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 7
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 4
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- GBHRVZIGDIUCJB-UHFFFAOYSA-N hydrogenphosphite Chemical compound OP([O-])[O-] GBHRVZIGDIUCJB-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229940056501 technetium 99m Drugs 0.000 description 3
- IUTCEZPPWBHGIX-UHFFFAOYSA-N tin(2+) Chemical compound [Sn+2] IUTCEZPPWBHGIX-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- GQZXNSPRSGFJLY-UHFFFAOYSA-N hydroxyphosphanone Chemical compound OP=O GQZXNSPRSGFJLY-UHFFFAOYSA-N 0.000 description 2
- 229940005631 hypophosphite ion Drugs 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 description 1
- NYYSPVRERVXMLJ-UHFFFAOYSA-N 4,4-difluorocyclohexan-1-one Chemical compound FC1(F)CCC(=O)CC1 NYYSPVRERVXMLJ-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000007435 diagnostic evaluation Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- AQSJGOWTSHOLKH-UHFFFAOYSA-N phosphite(3-) Chemical class [O-]P([O-])[O-] AQSJGOWTSHOLKH-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 1
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 150000003606 tin compounds Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0476—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from monodendate ligands, e.g. sestamibi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Optics & Photonics (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4073993A | 1993-03-31 | 1993-03-31 | |
| PCT/US1994/003389 WO1994022496A1 (fr) | 1993-03-31 | 1994-03-29 | Formulations radiopharmaceutiques ayant des agents reducteurs non stanneux |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO953756D0 NO953756D0 (no) | 1995-09-22 |
| NO953756L NO953756L (no) | 1995-09-22 |
| NO313954B1 true NO313954B1 (no) | 2003-01-06 |
Family
ID=21912668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19953756A NO313954B1 (no) | 1993-03-31 | 1995-09-22 | Fremgangsmåte for fremstilling av et radiofarmasöytisk avbildingsmiddel |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5662882A (fr) |
| EP (1) | EP0692978A4 (fr) |
| JP (1) | JPH08508500A (fr) |
| AU (1) | AU6493894A (fr) |
| CA (1) | CA2158249A1 (fr) |
| FI (1) | FI954598A0 (fr) |
| HU (1) | HU222574B1 (fr) |
| MX (1) | MXPA94002323A (fr) |
| NO (1) | NO313954B1 (fr) |
| WO (1) | WO1994022496A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5744120A (en) * | 1993-03-30 | 1998-04-28 | The Dupont Merick Pharmaceutical Company | Ternary radiopharmaceutical complexes |
| US20050267302A1 (en) * | 1995-12-11 | 2005-12-01 | G.D. Searle & Co. | Eplerenone crystalline form exhibiting enhanced dissolution rate |
| US6416733B1 (en) | 1996-10-07 | 2002-07-09 | Bristol-Myers Squibb Pharma Company | Radiopharmaceuticals for imaging infection and inflammation |
| US6537520B1 (en) | 1998-03-31 | 2003-03-25 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
| AU2371400A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | Vitronectin receptor antagonist pharmaceuticals |
| US6656448B1 (en) | 2000-02-15 | 2003-12-02 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
| GB0004751D0 (en) * | 2000-03-01 | 2000-04-19 | British Nuclear Fuels Plc | Waste treatment |
| WO2001087354A2 (fr) | 2000-05-17 | 2001-11-22 | Bristol-Myers Squibb Pharma Company | Utilisation de radioligands a petites molecules en vue de rechercher des inhibiteurs de production d'amyloide-beta et destine a l'imagerie diagnostique |
| BR0106717A (pt) | 2000-06-01 | 2002-04-16 | Bristol Myers Squibb Pharma Co | Compostos, composição farmacêutica e usos dos compostos de lactama inovadora |
| JP2004512382A (ja) | 2000-11-03 | 2004-04-22 | ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー | 心臓灌流および心臓炎症の２核種同時イメージング |
| US7344702B2 (en) | 2004-02-13 | 2008-03-18 | Bristol-Myers Squibb Pharma Company | Contrast agents for myocardial perfusion imaging |
| KR100445971B1 (ko) * | 2002-04-15 | 2004-08-25 | 한국원자력연구소 | 수소화붕소 교환수지를 이용한 테크네튬 또는 레늄의표지방법 |
| US20050106100A1 (en) * | 2003-09-03 | 2005-05-19 | Harris Thomas D. | Compounds containing matrix metalloproteinase substrates and methods of their use |
| US7485283B2 (en) | 2004-04-28 | 2009-02-03 | Lantheus Medical Imaging | Contrast agents for myocardial perfusion imaging |
| AU2006266074A1 (en) * | 2005-06-30 | 2007-01-11 | Bristol-Myers Squibb Pharma Company | Hydrazide conjugates as imaging agents |
| US7824659B2 (en) | 2005-08-10 | 2010-11-02 | Lantheus Medical Imaging, Inc. | Methods of making radiolabeled tracers and precursors thereof |
| PT2257315T (pt) | 2008-02-29 | 2020-01-27 | Lantheus Medical Imaging Inc | Agentes de contraste para aplicações incluindo imagiologia de perfusão |
| PT2419096T (pt) | 2009-04-15 | 2020-02-19 | Lantheus Medical Imaging Inc | Estabilização de composições radiofarmacêuticas utilizando ácido ascórbico |
| PT2534136T (pt) | 2010-02-08 | 2017-12-15 | Lantheus Medical Imaging Inc | Métodos para sintetizar agentes de imagiologia, e seus intermediários |
| AU2013203000B9 (en) | 2012-08-10 | 2017-02-02 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3749556A (en) * | 1971-08-19 | 1973-07-31 | Medi Physics Inc | Radiopharmaceutical generator kit |
| CA1029721A (fr) * | 1973-04-23 | 1978-04-18 | Theodore F. Bolles | Production et usages des complexes marques technetium |
| US3983227A (en) * | 1973-05-23 | 1976-09-28 | The Procter & Gamble Company | Dry mixture containing diphosphonates and a stannous salt useful in the preparation of Tc99M containing bone scanning agents |
| US4272503A (en) * | 1978-05-25 | 1981-06-09 | New England Nuclear Corporation | Reductant composition for technetium-99m and method for making technetium-99m labelled ligands |
| US4229427A (en) * | 1978-06-28 | 1980-10-21 | The Procter & Gamble Company | Radioactive scanning agents with hydroquinone stabilizer |
| GB2046000B (en) * | 1979-02-27 | 1982-11-24 | Radiochemical Centre Ltd | Method and container for reducing pertechnetate |
| GB8310438D0 (en) * | 1983-04-18 | 1983-05-25 | Amersham Int Plc | Bone-seeking complexes of technetium-99m |
| ATE66469T1 (de) * | 1985-01-14 | 1991-09-15 | Neorx Corp | Metall-radionuklid markiertes protein fuer diagnose und therapie. |
| US4795626A (en) * | 1985-05-10 | 1989-01-03 | University Of Cincinnati | 99m Tc.sup.(III) myocardial imaging agents which are non-reducable in vivo |
| ATE52189T1 (de) * | 1985-07-05 | 1990-05-15 | Causse Jean Etienne | Verfahren zur reduktion von pertechnetat. |
| GB8615916D0 (en) * | 1986-06-30 | 1986-08-06 | Amersham Int Plc | Bone-seeking complexes of technetium-99m |
| EP0313712B1 (fr) * | 1987-10-30 | 1992-07-29 | SORIN BIOMEDICA S.p.A. | Compositions radiodiagnostiques stables et leur préparation |
| EP0381713B1 (fr) * | 1988-04-29 | 1994-01-19 | Mallinckrodt, Inc. | Agents chelateurs de diaminedithiol pour substances radiopharmaceutiques |
| US5202109A (en) * | 1988-06-10 | 1993-04-13 | Neorx Corporation | Conjugates for bone imaging and bone cancer therapy |
| US4925650A (en) * | 1988-11-16 | 1990-05-15 | Mallinckrodt, Inc. | Technetium -99m complex for examining the renal function |
| US4957728A (en) * | 1989-05-19 | 1990-09-18 | University Of Cincinnati | Kit for preparing Tc (III)-99m myocardial imaging agents that are effective in humans |
| US5069900A (en) * | 1989-08-28 | 1991-12-03 | E. R. Squibb & Sons, Inc. | Boronic acid adducts of technetium-99m dioxime-imine complexes |
| US5145636A (en) * | 1989-10-02 | 1992-09-08 | Neorx Corporation | Soluble irradiation targets and methods for the production of radiorhenium |
| FR2664166A1 (fr) * | 1990-07-04 | 1992-01-10 | Cis Bio Int | Procede de preparation de complexes nitruro de metaux de transition utilisables comme produits radiopharmaceutiques ou pour la synthese de nouveaux produits radiopharmaceutiques. |
| US5112594A (en) * | 1991-04-04 | 1992-05-12 | Mallinckrodt Medical, Inc. | Kit for preparing a technetium-99m myocardial imaging agent |
| US5317091A (en) * | 1991-02-27 | 1994-05-31 | Akzo N.V. | Technetium-99m labeling of proteins |
| GB9118183D0 (en) * | 1991-08-23 | 1991-10-09 | Solanki Kishor K | Imaging of infections |
| DE4128181C2 (de) * | 1991-08-24 | 1996-02-29 | Forschungszentrum Juelich Gmbh | Technetium-Komplexe, Verfahren zur Herstellung derselben und Applikationskits für die Bildung von Technetium-Komplexen |
| US5300280A (en) * | 1992-02-14 | 1994-04-05 | Mallinckrodt Medical, Inc. | Stabilized radiopharmaceutical kits |
-
1994
- 1994-03-29 CA CA002158249A patent/CA2158249A1/fr not_active Abandoned
- 1994-03-29 MX MXPA94002323A patent/MXPA94002323A/es unknown
- 1994-03-29 AU AU64938/94A patent/AU6493894A/en not_active Abandoned
- 1994-03-29 JP JP6522283A patent/JPH08508500A/ja not_active Ceased
- 1994-03-29 HU HU9502859A patent/HU222574B1/hu not_active IP Right Cessation
- 1994-03-29 EP EP94912332A patent/EP0692978A4/fr not_active Withdrawn
- 1994-03-29 WO PCT/US1994/003389 patent/WO1994022496A1/fr not_active Application Discontinuation
-
1995
- 1995-03-23 US US08/410,642 patent/US5662882A/en not_active Expired - Fee Related
- 1995-09-22 NO NO19953756A patent/NO313954B1/no unknown
- 1995-09-28 FI FI954598A patent/FI954598A0/fi not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HU9502859D0 (en) | 1995-11-28 |
| HU222574B1 (hu) | 2003-08-28 |
| CA2158249A1 (fr) | 1994-10-13 |
| EP0692978A1 (fr) | 1996-01-24 |
| AU6493894A (en) | 1994-10-24 |
| NO953756D0 (no) | 1995-09-22 |
| HUT75669A (en) | 1997-05-28 |
| FI954598A (fi) | 1995-09-28 |
| JPH08508500A (ja) | 1996-09-10 |
| WO1994022496A1 (fr) | 1994-10-13 |
| NO953756L (no) | 1995-09-22 |
| US5662882A (en) | 1997-09-02 |
| FI954598A0 (fi) | 1995-09-28 |
| MXPA94002323A (es) | 2002-06-18 |
| EP0692978A4 (fr) | 1998-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO313954B1 (no) | Fremgangsmåte for fremstilling av et radiofarmasöytisk avbildingsmiddel | |
| EP0038756B1 (fr) | Complexes lipophiles cationiques du 99m technétium utilisables pour la visualisation myocardiale et hépatobiliaire | |
| Moerlein et al. | The chemistry of gallium and indium as related to radiopharmaceutical production | |
| DK172154B1 (da) | Isonitrilkompleks omfattende et radionuclid, middel til anvendelse ved mærkning, afbildning eller detektering og indeholdende et sådant kompleks, kit til fremstilling af et sådant kompleks, og fremgangsmåde til mærkning af en celle eller et liposom in vitro | |
| Srivastava et al. | Technetium-labeled compounds | |
| Hambright et al. | Chemistry of technetium radiopharmaceuticals. I. Exploration of the tissue distribution and oxidation state consequences of technetium (IV) in Tc-Sn-gluconate and Tc-Sn-EHDP using carrier 99Tc | |
| US4489054A (en) | Cationic lipophilic complexes of 99m Tc and their use for myocardial and hepatobiliary imaging | |
| Zhang et al. | Potential 67Ga radiopharmaceuticals for myocardial imaging: tris (1-aryl-3-hydroxy-2-methyl-4-pyridinonato) gallium (III) complexes | |
| US6936240B2 (en) | Method for the preparation of technetium or rhenium complex for radiopharmaceuticals | |
| EP0472665B1 (fr) | AGENTS DE FORMATION D'IMAGES DU MYOCARDE A BASE D'UN COMPLEXE 99m Tc(III), AGISSANT CHEZ L'HOMME | |
| Sidorenko et al. | Higher technetium (I) carbonyls and possibility of using them in nuclear medicine: problems and prospects | |
| EP2351758B1 (fr) | Complexes métalliques, procédé de production de ces derniers, et agents radio-pharmaceutiques les utilisant | |
| WO1992007859A1 (fr) | COMPLEXE AU TECHNETIUM 99m UTILE POUR EXAMINER LA FONCTION RENALE | |
| CA1300608C (fr) | Agents de visualisation du myocarde 99 mtc (iii) ayant un potentiel redox pratiquement negatif in vivo | |
| US4957728A (en) | Kit for preparing Tc (III)-99m myocardial imaging agents that are effective in humans | |
| NO852202L (no) | Middel for fremstilling av technetium-komplekser og anvendelse av midlet. | |
| US5081232A (en) | Complexes of tc99m radiopharmaceuticals | |
| Srivastava et al. | Tumor uptake of radioruthenium compounds | |
| EP0138384B1 (fr) | Visualisation d'infarctus cardiaques à l'aide de métaux radioactifs compléxés avec des dérivés phosphonates | |
| Vilček et al. | 99mTc-labelled compounds prepared with sodium dithionite as reducing agent | |
| CZ531690A3 (en) | Cement-input non-radioactive intensifier for preparing a stable enantiomeric form of kidneys function diagnosing agent technetium -99m mercaptoacetyl triglycine | |
| Witthuhn | Development of Tricarbonyl Re and Tc-99m Complexes for Radiopharmaceutical and Hanford Waste Applications | |
| Webb | Radiopharmaceutical applications of technetium 3-oxy-4-pyrones and 3-oxy-4-pyridinones and gallium 3-oxy-4-pyridinones | |
| EP0548245A1 (fr) | Complexe de radionuclides metalliques comprenant des ligands isonitrites | |
| Cox | Solid-phase labelling. An improved method for the preparation of technetium-labelled radiopharmaceuticals |